Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Primed In Situ Labelling in Determination of HER-2 Gene Amplification and CEN-17 Status in Breast Cancer Tissue

  • Salimi, Mahdieh (Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University) ;
  • Mozdarani, Hossein (Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University) ;
  • Majidzadeh-A, Keivan (Iranian Centre for Breast Cancer, Academic Centre for Education, Culture and Research)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Considerable attention has been given to the accuracy of HER-2 testing and the correlation between the results of different testing methods. This interest reflects the growing importance of HER-2 status in the management of patients with breast cancer. In this study the detection of HER-2 gene and centromere 17 status was evaluated using dual-colour primed in situ labelling (PRINS) in comparison with fluorescence in situ hybridization (FISH). These two methods were evaluated on a series of 27 formalin fixed paraffin embedded breast carcinoma tumours, previously tested for protein overexpression by HercepTest (grouped into Hercep 1+/0, 2+ and 3+). HER-2 gene amplification (ratio${\geq}2.2$) by PRINS was found in 3:3, 6:21 and 0:3 in IHC 3+, 2+ and 1+/0 cases, respectively. Comparing FISH and IHC (immunohistochemistry), showed the same results as for PRINS and IHC. Chromosome 17 aneusomy was found in 10 of 21 IHC 2+ cases (47.6%), of which 1 (10%) showed hypodisomy (chromosome 17 copy number per cell${\leq}1.75$), 7 (70%) showed low polysomy (chromosome 17 copy number per cell=2.26 - 3.75) and 2 (20%) showed high polysomy (chromosome 17 copy number per cell ${\geq}3.76$). The overall concordance of detection of HER-2 gene amplification by FISH and PRINS was 100% (27:27). Furthermore, both the level of HER-2 amplification and copy number of CEN17 analysis results correlated well between the two methods. In conclusion, PRINS is a reliable, reproducible technique and in our opinion can be used as an additional test to determine HER-2 status in breast tumours.

Keywords

References

  1. Al-Khattabi H, Kelany A, Buhmeida A, et al (2010). Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer. Anticancer Res, 30, 4081-8.
  2. Arnould L, Denoux Y, MacGrogan G, et al (2003). Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER-2 status in breast cancer. Br J Cancer, 88, 1587-91. https://doi.org/10.1038/sj.bjc.6600943
  3. Bottema CDK, Sommer SS (1993). PCR amplification of specific alleles: rapid detection of known mutations and polymorphisms. Mutat Res, 288, 93-102. https://doi.org/10.1016/0027-5107(93)90211-W
  4. Carlsson J, Nordgren H, Sjostrom J, et al (2004). HER-2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer, 90, 2344-8. https://doi.org/10.1038/sj.bjc.6601881
  5. Cobleigh MA, Vogel CL, Tripathy D, et al (1999). Multinational study of the efficacy and safety of humanized anti- HER-2 monoclonal antibody in women who have HER-2 -overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, 2639-48. https://doi.org/10.1200/JCO.1999.17.9.2639
  6. Coullin P, Andréo B, Charlieu JP, et al (1997). Primed in situ (PRINS) labelling with Alu and satellite primers for rapid characterization of human chromosomes in hybrid cell lines. Chromosome Res, 5, 307-12. https://doi.org/10.1023/B:CHRO.0000038761.15856.4d
  7. De Korte MA, de Vries EG, Lub-de Hooge MN, et al (2007). 111Indium-trastuzumab visualizes myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumabrelated cardiotoxicity. Eur J Cancer, 43, 2046-51. https://doi.org/10.1016/j.ejca.2007.06.024
  8. Downs-Kelly E, Pettay J, Hicks D, et al (2005). Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER-2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol, 29, 1505-11. https://doi.org/10.1097/01.pas.0000172294.67409.4f
  9. Downs-Kelly E, Yoder BJ, Stoler M, et al (2005). The influence of polysomy 17 on HER-2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol, 29, 1221-7. https://doi.org/10.1097/01.pas.0000165528.78945.95
  10. Dowsett M, Hanna WM, Kockx M, et al (2007). Standardization of HER-2 testing: results of an international proficiencytesting ring study. Mod Pathol, 20, 584-91. https://doi.org/10.1038/modpathol.3800774
  11. Dowsett M, Hanby AM, Laing R, et al (2007). National HER-2 Consultation Steering Group: HER-2 testing in the UK: consensus from a national consultation. J Clin Pathol, 60, 685-9. https://doi.org/10.1136/jcp.2006.044321
  12. Dybdal N, Leiberman G, Anderson S, et al (2005). Determination of HER-2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat, 93, 3-11.
  13. Eccles SA (2002). The role of c-erbB-2/HER-2 /neu in breast cancer progression and metastases. J Mammary Gland Biol Neoplasia, 6, 393-406. https://doi.org/10.1023/A:1014730829872
  14. Ellis CM, Dyson MJ, Stephenson TJ, et al (2005). HER-2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol, 58, 710-4. https://doi.org/10.1136/jcp.2004.023424
  15. Fagnani F, Colin X, Arveux P, et al (2007). Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER-2 positive early breast cancer. Bull Cancer, 94, 711-20.
  16. Gancberg D, Jarvinen T, di Leo A, et al (2002). Evaluation of HER-2/neu protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER-2/neu testing. Breast Cancer Res Treat, 74, 113-20 https://doi.org/10.1023/A:1016146130767
  17. García-Caballero T, Grabau D, Green AR, et al (2010). Determination of HER-2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology, 56, 472-80. https://doi.org/10.1111/j.1365-2559.2010.03503.x
  18. Garrison LP Jr, Lubeck D, Lalla D, et al (2007). Costeffectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER-2 -postive breast cancer. Cancer, 110, 489-98. https://doi.org/10.1002/cncr.22806
  19. Ghaffari SR, Sabokbar T, Dastan J, et al (2011). HER-2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ h ybridisation (FISH). Asian Pac J Cancer Prev, 12, 1031-4.
  20. Gjerdrum LM, Lielpetere I, Rasmussen LM, et al (2001). Laserassisted microdissection of membrane-mounted paraffin sections for polymerase chain reaction analysis: identification of cell populations using immunohistochemistry and in situ hybridization. J Mol Diagn, 3, 105-10. https://doi.org/10.1016/S1525-1578(10)60659-9
  21. Gupta D, Middleton LP, Whitaker MJ, et al (2003). Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogenes in breast cancer. Am J Clin Pathol, 119, 381-7. https://doi.org/10.1309/P40P2EAD42PUKDMG
  22. Hanna W, Kahn H. J, Trudeau M (1999). Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Modern Pathology, 8, 827-34.
  23. Harris L, Fritsche H, Mennel R, et al (2007). American Society of Clinical Oncology. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 33, 5287-312.
  24. Herrington C, Flannery M, McGee J (1990). Application of non-isotopic in situ hybridization and polymerase chain reaction to the analysis of human and viral genes. In: In situ hybridization (J.M. Polak and J. Mc Gee eds.), Oxford: Oxford University Press.
  25. Hyun CL, Lee HE, Kim KS, et al (2008). The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol, 61, 317-321. https://doi.org/10.1136/jcp.2007.050336
  26. Kadandale JS, Wachtel SS, Tunca Y, et al (2000). Localization of primed in situ labeling in XX and XY sex reversal. Am J Med Genet, 95, 71-4. https://doi.org/10.1002/1096-8628(20001106)95:1<71::AID-AJMG14>3.0.CO;2-Y
  27. Kadandale JS, Tunca Y, Tharapel AT (2000). Chromosomal localization of single copy genes SRY and SOX3 by primed in situ labeling (PRINS). Microb Comp Genomics, 5, 71-4. https://doi.org/10.1089/10906590050179756
  28. Kim GY, Oh YL (2004). Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma. Cytopathology, 15, 315-20. https://doi.org/10.1111/j.1365-2303.2004.00214.x
  29. Koch GG, Landis JR, Freeman JL, et al (1977). A general methodology for the analysis of experiments with repeated measurement of categorical data. Biometrics, 33, 133-58. https://doi.org/10.2307/2529309
  30. Koch JE, Kolvraa S, Petersen KB, et al (1989). Oligonucleotidepriming methods for the chromosome-specific labeling of alpha satellite DNA in situ. Chromosoma, 98, 259-65. https://doi.org/10.1007/BF00327311
  31. Koch J (1992). Non-radioactive labeling and detection of nucleic acids in situ by "Primed In Situ Labeling (PRINS). In: Nonradioactive in situ hybridization; Application Manual (edited by Boehringer Mannheim Biochemica), 31-3.
  32. Krabchi K, Gros-Louis F, Yan J, et al (2001). Quantification of all fetal nucleated cells in maternal blood between the 18th and 22nd weeks of pregnancy using molecular cytogenetic techniques. Clin Genet, 60, 145-50. https://doi.org/10.1034/j.1399-0004.2001.600209.x
  33. Krabchi K, Gadji M, Forest JC, et al (2006). Quantification of all fetal nucleated cells in maternal blood in different cases of aneuploidies. Clin Genet, 69, 145-54. https://doi.org/10.1111/j.1399-0004.2005.00564.x
  34. Lal P, Salazar PA, Ladanyi M, et al (2003). Impact of polysomy 17 on Her-2/neu immunohistochemistry in breast carcinomas without Her-2/neu gene amplification. J Molec Diagnostics, 5, 155-9. https://doi.org/10.1016/S1525-1578(10)60467-9
  35. Mennicke K, Yang J, Hinrichs F, et al (2003). Validation of primed in situ labeling for interphase analysis of chromosomes 18, X, and Y in uncultured amniocytes. Fetal Diagn Ther, 18, 114-21. https://doi.org/10.1159/000068072
  36. Millar JA, Millward MJ (2007). Cost effectiveness of trastuzumab in the early breast cancer: a lifetime model. Pharmocoeconomics, 25, 429-42. https://doi.org/10.2165/00019053-200725050-00006
  37. Moasser MM, Basso A, Averbuch SD, et al (2001). The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER-2 -driven signaling and suppresses the growth of HER-2 -overexpressing tumor cells. Cancer Res, 61, 7184-8.
  38. Moerland E, van Hezik RL, van der Aa TC, et al (2006). Detection of HER-2 amplification in breast carcinomas: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH) combined with automated spot counting. Cell Oncol, 28, 151-9.
  39. Mrozkowiak A, Olszewski WP, Piaścik A, et al (2004). HER-2 status in breast cancer determined by IHC and FISH: comparison of the results. Pol J Pathol, 55, 165-71.
  40. Nitta H, Hauss-Wegrzyniak B , Lehrkamp M, et al (2008). Development of automated brightfield double in Situ hybridization (BDISH) application for HER-2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER-2 fluorescence in Situ hybridization (FISH). Diagnostic Pathology, 3, 41. https://doi.org/10.1186/1746-1596-3-41
  41. Norum J, Olsen JA, Wist EA, et al (2007). Trastuzumab in adjuvant breast cancer therapy. A model based costeffectivemess analysis. Acta Oncol, 46, 153-64. https://doi.org/10.1080/02841860601096841
  42. Orsetti B, Lefort G, Boulot P, et al (1998). Fetal cells in maternal blood: the use of primed in situ (PRINS) labelling technique for fetal cell detection and sex assessment. Prenat Diagn, 18, 1014-22. https://doi.org/10.1002/(SICI)1097-0223(1998100)18:10<1014::AID-PD382>3.0.CO;2-Z
  43. Owens MA, Horten BC, Da Silva MM (2004). HER-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9. https://doi.org/10.3816/CBC.2004.n.011
  44. Panjwani P, Epari S, Karpate A, et al (2010). Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian J Med Res, 132, 287-94.
  45. Park S, Park HS, Koo JS, et al (2011). Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer, (in press)
  46. Pellestor F, Girardet A, Andreo B, et al (1996). The PRINS technique: potential use for rapid preimplantation embryochromosome screening. Mol Hum Reprod, 2, 135-8. https://doi.org/10.1093/molehr/2.2.135
  47. Pellestor F (1998). What PRINS can do for you. Med Sci, 14, 935-8.
  48. Pellestor F (2006). In situ aneuploidy assessment in human sperm: the use of primed in situ and peptide nucleic acid- fluorescence in situ hybridization techniques. Asian J Androl, 8, 387-92. https://doi.org/10.1111/j.1745-7262.2006.00137.x
  49. Perez EA, Roche PC, Jenkins RB, et al (2002). HER-2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc, 77, 148-54. https://doi.org/10.1016/S0025-6196(11)62329-X
  50. Phillips KA, Marshall D A, Haas JS, et al (2009). Clinical practice patterns and cost-effectiveness of HER-2 Testing strategies in breast cancer patients. Cancer, 115, 5166-74. https://doi.org/10.1002/cncr.24574
  51. Rasmussen BB, Andersson M, Christensen IJ, et al (2008). Evaluation of and quality assurance in HER-2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol, 47, 784-8. https://doi.org/10.1080/02841860801989779
  52. Rosa FE, Silveira SM, Silveira CG, et al (2009). Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer, 23, 90-?.
  53. Ross JS, Fletcher JA (1999). HER-2/neu (c-erb-B2) gene and protein in breast cancer. Clin Pathol, 112, 53-67.
  54. Ross JS, Symmans WF, Pusztai L, et al (2007). Standardizing slide-based assays in breast cancer: hormone receptors, HER-2 , and sentinel lymph nodes. Clin Cancer Res, 13, 2831-5. https://doi.org/10.1158/1078-0432.CCR-06-2522
  55. Ross JS, Slodkowska E A, Symmans W F, et al (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist, 14, 320-68. https://doi.org/10.1634/theoncologist.2008-0230
  56. Shah S S, Wang Y, Tull J, et al (2009). Effect of high copy number of HER-2 associated with polysomy 17 on HER-2 protein expression in invasive breast carcinoma. Diagnostic Molecular Pathology, 18, 30-3. https://doi.org/10.1097/PDM.0b013e31817c1af8
  57. Shah S, Chen B (2010). Testing for HER-2 in breast cancer: A continuing evolution. Patholog Res Int, 6, 903202-7.
  58. Tetu B, Brisson J, Plante V, et al (1998). 53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol, 11, 823-30.
  59. Singhai R, Patil V, Patil A (2011). Immunohistochemical (IHC) HER-2/neu and fluorescence in situ hybridization (FISH) gene amplification of breast cancer in Indian women. Asian Pac J Cancer Prev, 12, 179-83.
  60. Speel EJ, Lawson D, Hopman AH, et al (1995). Multi-PRINS: multiple sequential oligonucleotide primed in situ DNA synthesis reactions label specific chromosomes and produce bands. Hum Genet, 95, 29-33.
  61. Tharapel SA. Kadandale JS (2002). Primed in situ labeling (PRINS) for evaluation of gene deletions in cancer. Am J Medical Genetics, 107, 123-6. https://doi.org/10.1002/ajmg.10105
  62. Torrisi R, Rotmensz N, Bagnardi V, et al (2007). HER-2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer, 43, 2339-44. https://doi.org/10.1016/j.ejca.2007.07.033
  63. Tubbs RR, Pettay J, Roche P, et al (2000). Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH). A fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. J Mol Diagn, 2, 78-83. https://doi.org/10.1016/S1525-1578(10)60620-4
  64. Tubbs R, Pettay J, Skacel M, et al (2002). Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of HER- 2/neu gene amplification. Am J Pathol, 160, 1589-95. https://doi.org/10.1016/S0002-9440(10)61106-6
  65. Tubbs RR, Pettay JD, Roche PC, et al (2001). Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol, 19, 2714-21. https://doi.org/10.1200/JCO.2001.19.10.2714
  66. Vanden Bempt I, Van Loo P, Drijkoningen M, et al (2008). Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol, 26, 4869-74. https://doi.org/10.1200/JCO.2007.13.4296
  67. Van de Vijver M, Bilous M, Hanna W, et al (2007). Chromogenic in situ hybridisation for the assessment of HER-2 status in breast cancer: an international validation ring study. Breast Cancer Res, 9, 68-9. https://doi.org/10.1186/bcr1776
  68. Wang S, Saboorian M H, Frenkel E P, et al (2002). Aneusomy17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Modern Pathology, 15,137-45. https://doi.org/10.1038/modpathol.3880505
  69. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45. https://doi.org/10.1200/JCO.2006.09.2775
  70. Yan L, Bronsard M, Drouin R (2001). Creating a new color by omission of 3' end blocking step for simultaneous detection of different chromosomes in multi-PRINS technique. Chromosoma, 109, 565-70. https://doi.org/10.1007/s004120000111
  71. Yarden Y, Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2, 127-37. https://doi.org/10.1038/35052073
  72. Yeh IT, Salazar P. A., Ladanyi M., et al (2009). Clinical validation of an array CGH test for HER-2 status in breast cancer reveals that polysomy 17 is a rare event. Modern Pathology, 22, 1169-75. https://doi.org/10.1038/modpathol.2009.78
  73. Zeng X, Liang ZY, Wu SF, et al (2006). Analysis of HER-2 gene status in breast cancer with HER-2 protein overexpression. Zhonghua Bing Li Xue Za Zhi, 35, 584-8.